Literature DB >> 9815967

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

M F Di Renzo1, M Olivero, A Giacomini, H Porte, E Chastre, L Mirossay, B Nordlinger, S Bretti, S Bottardi, S Giordano.   

Abstract

The c-met oncogene encodes the receptor for hepatocyte growth factor/scatter factor, a potent mitogen for epithelial cells that also promotes cell motility and invasiveness. We have studied the changes of c-met gene expression that occur during the progression of colorectal tumors. Sixteen adenomas, 123 primitive carcinomas, and 25 liver metastases were examined. In several instances it was possible to compare same-patient samples of normal colon mucosa against primary tumor and primary carcinoma against synchronous metastasis. The expression of the c-met gene was increased from 5- to 50-fold in about 50% of tumors, at any stage of progression, and in 70% of liver metastases. Overexpression was associated with amplification of the c-met gene in only 10% of carcinomas, but in 8 of 9 metastases examined. These data suggest that overexpression of the c-met oncogene contributes a selective growth advantage to neoplastic colorectal cells at any stage of tumor progression. Moreover, amplification appears to give a further selective advantage for the acquisition of metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815967

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  132 in total

Review 1.  Invasive growth: from development to metastasis.

Authors:  Paolo M Comoglio; Livio Trusolino
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Authors:  David Liska; Chin-Tung Chen; Thomas Bachleitner-Hofmann; James G Christensen; Martin R Weiser
Journal:  Clin Cancer Res       Date:  2010-11-22       Impact factor: 12.531

4.  PKC controls HGF-dependent c-Met traffic, signalling and cell migration.

Authors:  Stéphanie Kermorgant; Daniel Zicha; Peter J Parker
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

5.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 6.  Genomic diversity of colorectal cancer: Changing landscape and emerging targets.

Authors:  Daniel H Ahn; Kristen K Ciombor; Sameh Mikhail; Tanios Bekaii-Saab
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

7.  MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.

Authors:  Young Wha Koh; Yang-Soon Park; Hyo Jeong Kang; Ju Hyun Shim; Eunsil Yu
Journal:  Tumour Biol       Date:  2015-02-10

Review 8.  Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors.

Authors:  Christopher Christophi; Nadia Harun; Theodora Fifis
Journal:  J Gastrointest Surg       Date:  2008-01-08       Impact factor: 3.452

9.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

10.  Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.

Authors:  Xingnan Zheng; Kan He; Lin Zhang; Jian Yu
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.